Pregabalin for pain in fibromyalgia in adults.
BACKGROUND
This review updates part of an earlier Cochrane review on 'Pregabalin for acute and chronic pain in adults' (Moore 2009), and considers only fibromyalgia pain.Antiepileptic drugs have been used in pain management since the 1960s. Pregabalin is an antiepileptic drug also used in management of chronic pain conditions, including fibromyalgia. Pain response with pregabalin is associated with major benefits for other symptoms, and improved quality of life and function in people with chronic painful conditions.


OBJECTIVE
To assess the analgesic efficacy and adverse events of pregabalin for pain in fibromyalgia in adults, compared with placebo or any active comparator.


METHODS
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to May 2009 for the original review and to 16 March 2016 for this update. We also searched the reference lists of retrieved studies and reviews, and online clinical trial registries.


METHODS
We included randomised, double-blind trials of eight weeks' duration or longer, comparing pregabalin with placebo or another active treatment for relief of pain in fibromyalgia, and reporting on the analgesic effect of pregabalin, with subjective pain assessment by the participant.


METHODS
Two review authors independently extracted data and assessed trial quality and potential bias. Primary outcomes were participants with moderate pain relief (at least 30% pain relief over baseline or much or very much improved on Patient Global Impression of Change scale (PGIC)) or substantial pain relief (at least 50% pain relief over baseline or very much improved on PGIC). Where pooled analysis was possible, we used dichotomous data to calculate risk ratio and number needed to treat (NNT), using standard methods. We assessed the quality of the evidence using GRADE (Grading of Recommendations Assessment, Development and Evaluation) and created 'Summary of findings' tables.


RESULTS
Our searches identified two new published studies with classic design, and one new published study with an enriched enrolment randomised withdrawal (EERW) design.We included eight studies. Five (3283 participants) had a classic design in which participants were randomised at the start of the study to pregabalin (150, 300, 450, or 600 mg daily) or placebo, with assessment after 8 to 13 weeks of stable treatment. No studies included active comparators. Studies had low risk of bias, except that the last observation carried forward (LOCF) imputation method used in analyses of the primary outcomes could overestimate treatment effect.Pregabalin increased the number of participants experiencing substantial benefit (at least 50% pain intensity reduction after 12 or 13 weeks' stable treatment (450 mg: RR 1.8, 95% CI 1.4 to 2.1, 1874 participants, 5 studies, high quality evidence)). Substantial benefit with pregabalin 300 to 600 mg was experienced by about 14% of participants with placebo, but about 9% more with pregabalin 300 to 600 mg (22% to 24%) (high quality evidence). Pregabalin increased the number of participants experiencing moderate benefit (at least 30% pain intensity reduction after 12 or 13 weeks' stable treatment) (450 mg: RR 1.5, 95% CI (1.3 to 1.7), 1874 participants, 5 studies, high quality evidence). Moderate benefit with pregabalin 300 to 600 mg was experienced by about 28% of participants with placebo, but about 11% more with pregabalin 300 to 600 mg (39% to 43%) (high quality evidence). A similar magnitude of effect was found using PGIC of 'very much improved' and 'much or very much improved'. NNTs for these outcomes ranged between 7 and 14 (high quality evidence).A small study (177 participants) compared nightly with twice-daily pregabalin, and concluded there was no difference in effect.Two studies (1492 participants began initial dose titration, 687 participants randomised) had an EERW design in which those with good pain relief after titration were randomised, double blind, to continuing the effective dose (300 to 600 mg pregabalin daily) or a short down-titration to placebo for 13 or 26 weeks. We calculated the outcome of maintained therapeutic response (MTR) without withdrawal, equivalent to a moderate benefit. Of those randomised, 40% had MTR with pregabalin and 20% with placebo (high quality evidence). The NNT was 5, but normalised to the starting population tested it was 12. About 10% of the initial population would have achieved the MTR outcome, similar to the result from studies of classic design. MTR had no imputation concerns.The majority (70% to 90%) of participants in all treatment groups experienced adverse events. Specific adverse events were more common with pregabalin than placebo, in particular dizziness, somnolence, weight gain, and peripheral oedema, with number needed to harm of 3.7, 7.4, 18, and 19 respectively for all doses combined (high quality evidence). Serious adverse events did not differ between active treatment groups and placebo (very low quality evidence). Withdrawals for any reason were more common with pregabalin than placebo only with the 600 mg dose in studies of classic design. Withdrawals due to adverse events were about 10% higher with pregabalin than placebo, but withdrawals due to lack of efficacy were about 6% lower (high quality evidence).


CONCLUSIONS
Pregabalin 300 to 600 mg produces a major reduction in pain intensity over 12 to 26 weeks with tolerable adverse events for a small proportion of people (about 10% more than placebo) with moderate or severe pain due to fibromyalgia. The degree of pain relief is known to be accompanied by improvements in other symptoms, quality of life, and function. These results are similar to other effective medicines in fibromyalgia (milnacipran, duloxetine).
Pain Research and Nuffield Department of Clinical Neurosciences (Nuffield Division of Anaesthetics), University of Oxford, Pain Research Unit, Churchill Hospital, Oxford, Oxfordshire, UK, OX3 7LE.
Sheena
S
Derry
Malene
M
Cording
Philip J
PJ
Wiffen
Simon
S
Law
Tudor
T
Phillips
R Andrew
RA
Moore
Brain. 2013 Jun;136(Pt 6):1857-67
23474848
JAMA. 2014 Apr 16;311(15):1547-55
24737367
Arthritis Rheum. 1990 Feb;33(2):160-72
2306288
Expert Opin Pharmacother. 2010 Oct;11(14):2275-80
20812879
Arthritis Care Res (Hoboken). 2010 May;62(5):600-10
20461783
Pain. 2012 Feb;153(2):265-268
22055553
Rheumatology (Oxford). 2015 Feb;54(2):270-7
25150513
Pain. 2008 Jun;136(3):419-431
18400400
Pain. 2013 Nov;154(11):2310-2316
23748113
Eur J Pain. 2014 Jan;18(1):67-75
23733529
Pain Pract. 2017 Jan;17(1):32-40
26892006
Arthritis Care Res (Hoboken). 2014 Feb;66(2):293-300
23983064
Curr Pain Headache Rep. 2013 Aug;17(8):356
23801009
Pain. 2010 May;149(2):360-364
20347225
Arthritis Res Ther. 2012 Oct 12;14(5):R217
23062189
Semin Arthritis Rheum. 2008 Jun;37(6):339-52
18191990
J Clin Epidemiol. 2013 Feb;66(2):151-7
22542023
J Rheumatol. 2011 Dec;38(12):2643-52
21965636
JAMA. 2014 Aug 13;312(6):623-30
25117131
BMJ. 2013 Dec 19;347:f7339
24355386
Clin Pharmacokinet. 2010 Oct;49(10):661-9
20818832
Pain. 2011 May;152(5):982-989
21414722
Pain. 2010 Sep;150(3):386-389
20627575
J Clin Pharm Ther. 2010 Dec;35(6):639-56
21054455
Cochrane Database Syst Rev. 2014 Jan 03;(1):CD007115
24385423
Contemp Clin Trials. 2015 Nov;45(Pt A):2-7
26232560
Lancet. 2012 Dec 15;380(9859):2163-96
23245607
Control Clin Trials. 1996 Feb;17(1):1-12
8721797
Pain. 2013 Aug;154(8):1216-23
23685006
Arthritis Care Res (Hoboken). 2011 Jun;63(6):808-20
20722042
Pain. 2015 Aug;156(8):1382-1395
25985142
Nat Rev Dis Primers. 2015 Aug 13;1:15022
27189527
Pain. 2010 Dec;151(3):592-597
20810214
Arthritis Care Res (Hoboken). 2013 Nov;65(11):1813-9
23861291
BMJ. 2013 May 03;346:f2690
23645858
Ger Med Sci. 2008 Dec 09;6:Doc14
19675740
Epilepsy Res. 2007 Feb;73(2):137-50
17126531
Pain. 2008 Apr;135(3):217-220
18258369
Cochrane Database Syst Rev. 2013 Oct 16;(10):CD010782
24129853
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD010292
23440848
J Clin Epidemiol. 2011 Dec;64(12):1294-302
21803546
Mod Rheumatol. 2013 Nov;23(6):1108-15
23203241
Br J Clin Pharmacol. 2008 Aug;66(2):266-75
18489611
BMC Musculoskelet Disord. 2011 Jun 03;12:125
21639874
J Pain. 2008 Feb;9(2):105-21
18055266
J Rheumatol. 2011 Jun;38(6):1113-22
21285161
Anaesthesia. 2013 Apr;68(4):400-12
23347230
Pain Res Manag. 2013 May-Jun;18(3):119-26
23748251
Ann Intern Med. 1987 Aug;107(2):224-33
3300460
Eur J Pain. 2013 Apr;17(4):581-6
23169685
Arthritis Rheum. 2013 Apr;65(4):1122-8
23280346
Schmerz. 2010 Aug;24(4):326-33
20602119
Curr Med Res Opin. 2014 Oct;30(10):2069-83
24867298
BMJ. 2013 Apr 24;346:f2304
23616031
BMC Musculoskelet Disord. 2007 Mar 09;8:27
17349056
Ann Rheum Dis. 2017 Feb;76(2):318-328
27377815
Cochrane Database Syst Rev. 2009 Jul 08;(3):CD007076
19588419
Rheumatol Int. 2012 Feb;32(2):417-26
21120487
Pain. 2010 May;149(2):194-201
20303665
Cochrane Database Syst Rev. 2015 Oct 20;(10):CD008244
26482422
Eur J Pain. 2014 Sep;18(8):1052-9
24453056
J Clin Epidemiol. 2013 Feb;66(2):158-72
22609141
BMC Musculoskelet Disord. 2010 Jul 05;11:150
20602781
J Pain. 2008 Sep;9(9):792-805
18524684
Schmerz. 2012 Jun;26(3):259-67
22760458
J Pain. 2010 Jun;11(6):505-21
20418173
Sleep Med. 2009 Jun;10(6):604-10
19410509
Pain Pract. 2014 Jan;14(1):79-94
23464879
Cochrane Database Syst Rev. 2014 Apr 27;(4):CD007938
24771480
Cochrane Database Syst Rev. 2012 Dec 12;12:CD008242
23235657
Am J Med. 2009 Dec;122(12 Suppl):S22-30
19962493
BMC Neurol. 2008 Aug 01;8:29
18673529
Eur J Anaesthesiol. 2011 Jun;28(6):427-32
21445017
J Pain. 2010 Oct;11(10):994-1003
20400378
Clin Ther. 2012 May;34(5):1092-102
22503162
Arthritis Care Res (Hoboken). 2012 Apr;64(4):597-606
22232085
BMC Neurol. 2011 May 25;11:55
21612589
Rheumatology (Oxford). 2010 Apr;49(4):706-15
20056767
J Clin Pharmacol. 2010 Jul;50(7):803-15
20357295
Arthritis Care Res (Hoboken). 2010 May;62(5):611-7
20191480
Ann Rheum Dis. 2010 Feb;69(2):374-9
19364730
Clin J Pain. 2012 Sep;28(7):609-14
22688598
Schmerz. 2012 Jun;26(3):268-75
22760459
J Rheumatol. 1999 Nov;26(11):2458-67
10555910
Arthritis Care Res (Hoboken). 2013 May;65(5):777-85
23424058
J Rheumatol. 2015 Jul;42(7):1237-44
26034150
Pain. 1998 Dec;78(3):209-216
9870574
Arthritis Rheum. 2005 Apr;52(4):1264-73
15818684
Arthritis Care Res (Hoboken). 2014 Jul;66(7):969-71
24127234
J Rheumatol. 2008 Mar;35(3):502-14
18278830
Pain Med. 2010 Jan;11(1):6-15
19732374
Pain. 2016 Jan;157(1):55-64
26270591
PLoS One. 2015 Sep 17;10(9):e0138024
26379048
Cochrane Database Syst Rev. 2013 Nov 11;(11):CD010567
24217986
Pain. 1997 Aug;72(1-2):95-7
9272792